摘要
通过古籍文献调研、中药现代研究进展及其研究成果的梳理,结合中医临床及中药学等学科领域内的专家学者的认识及应用经验,经讨论认为茺蔚子:功效主要为活血调经,清肝明目,活血利水降压。症靶为痛经、目赤翳障。标靶为血压、糖尿病性黄斑水肿。现代药理研究发现,茺蔚子及其有效成分具有收缩子宫、降低血压、营养神经、降低血脂等作用。本品无毒,但瞳孔散大者慎用。临床使用剂量为5~45 g。内服时当根据不同疾病,或同一疾病的不同阶段进行辨证使用,并积极探索茺蔚子用量与症靶、标靶的量效关系构建。
Based on the investigation of ancient books and literature, the progress and achievements of modern research on traditional Chinese medicine, and the understanding and application experience of experts and scholars in the field of clinical medicine and Chinese materia medica, it is believed that motherwort fruit has the following characteristics: Its effects mainly lie in promoting blood circulation for regulating menstruation, removing liver-fire for improving eyesight, promoting blood circulation for diuresis and lowering blood pressure. Its symptom targets are dysmenorrhea red eye and senile cataract. Its biochemical indicator targets are blood pressure and diabetes macular edema. Modern pharmacology deems that its effective components can act to contract uterus, lower blood pressure, nourish nerves, lower blood lipids, etc. With non-toxic effect, it also should be taken with caution for those with dilated pupils. Its clinical dosage range is 5-45g. When taken orally, according to different diseases or different stages of the same disease, motherwort fruit should be used based on a specific syndrome or the dose-effect relationship between the drug and its symptom targets and biochemical indicator targets.
作者
张海宇
张湘苑
陈科宇
张伟
ZHANG Haiyu;ZHANG Xiangyuan;CHEN Keyu;ZHANG Wei(Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Institute of Metabolic Diseases,Guang'amnen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;School of Basic Medicine,Gansu University of Chinese Medicine,Lanzhou 730000,China)
出处
《长春中医药大学学报》
2023年第1期1-4,共4页
Journal of Changchun University of Chinese Medicine
基金
中国科学院学部咨询评议项目(2021-ZW10-A-017)。
关键词
茺蔚子
症靶
标靶
痛经
血压
临床回归
motherwort fruit
symptom target
biochemical indicator target
dysmenorrhea
blood pressure
clinical sequel
